§ Mr. Mike Thomasasked the Secretary of State for Social Services whether he
662Wing and maintenance in the latest 12 months for which figures are available; and what are the projected costs for 1978-79.
§ Mr. DeakinsThe provision made in the estimates for the financial years 1977-78 and 1978-79 was as follows:
the per capita sums made available by his Department for capital revenue purposes in the county of Cornwall for each of the years 1976-77, 1977-78 and anticipated for 1978-79, and the extent to which this exceeds, or is less than, in comparable cash figures, the national averages per capita.
§ Mr. MoyleResource allocation to the Cornwall and Isles of Scilly Area Health Authority is the responsibility of the South Western Regional Health Authority. The information requested is as follows:
will take steps to ensure that patients, before participating in any assessment or trial of a drug with a product licence, are informed in writing of the nature of the 663W trial; and whether the doctor concerned will receive any benefit in cash or kind for participating in it.
§ Mr. MoyleNo. A product licence does not provide a basis for controlling communications between a doctor and his patient.
§ Mr. Mike Thomasasked the Secretary of State for Social Services if he will list in the Official Report all trials or assessments of drugs with a product licence involving general practitioners and 5,000 or more patients for which his Department has received protocols since 1st January 1974, specifying for each the
Proprietary name Generic name Manufacturer Date received One protocol Blocadren Timolol Maleate Merck, Sharpe & Dohme August 1976 Moduretic Amiloride Hydrochloride plus Hydrochlorothiazide. Tenormin Atenolol Stuart Pharmaceuticals January 1977 Slow Trasicor Oxprenolol Ciba February 1977 Clinoril Sulindac Merck, Sharpe & Dohme April 1977 Benoral Benorylate Winthrop June 1978 Fenopron Fenoprofen Dista June 1978 Lopressor Metoprolol tartrate Geigy June 1978
§ Mr. Mike Thomasasked the Secretary of State for Social Services if he will place in the Library the protocols for the general practitioner trials of each of the drugs Clinoril, Fenopron, Slow Trasicor, Visken, Tenormin, Lopressor, Dista and Disalcid, together with details of the number of general practitioners and patients involved; whether the patients are to be informed of their participation in the trial; and what reward was offered to participating general practitioners in each case.
§ Mr. MoyleI have placed in the Library protocols for the general practitioner trials for Clinoril, Fenopron, Tenormin, Lopressor and Disalcid. The latest protocols for Slow Trasicor and Visken have been requested, and will be placed in the Library when they are available. "Dista" is the name of a company, not that of a medicinal product. The number of general practitioners and patients involved is also given, together with the remuneration offered to practitioners. Whether patients are informed of their participation is a matter for the professional judgment of the practitioner concerned.